Completed PHASE2 INTERVENTIONAL NCT00003335

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies

Sponsor: Case Comprehensive Cancer Center

Conditions Graft Versus Host Disease Leukemia Lymphoma Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases

Interventions anti-thymocyte globulin busulfan cyclosporine melphalan methylprednisolone radiation therapy umbilical cord blood transplantation

Updated 6 times since 2017 Last updated: Mar 14, 2012 Started: Jan 31, 1998 Primary completion: Nov 30, 2007 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003335, this PHASE2 trial focuses on Graft Versus Host Disease and Leukemia and remains completed. Sponsored by Case Comprehensive Cancer Center, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States